NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma
Open Access
- 1 January 2015
- journal article
- review article
- Published by Wiley in BioMed Research International
- Vol. 2015, 1-9
Abstract
A pivotal strategy to improve NK cell-mediated antitumor activity involves the upregulation of activating ligands on tumor cells. Enhancement of NK cell-mediated recognition of multiple myeloma cells was reported by us and others showing increased surface expression of NKG2D and DNAM-1 ligands on tumor cells following treatment with a number of chemotherapeutic agents, such as genotoxic drugs or inhibitors of proteasome, histone deacetylases, GSK3, and HSP-90. These compounds have the capability to affect tumor survival but also to activate specific transduction pathways associated with the upregulation of different NK cell activating ligands on the tumor cells. Here, we will summarize and discuss the molecular pathways whereby these drugs can regulate the expression of NK cell activating ligands in multiple myeloma cells.Keywords
Funding Information
- Italian Association for Cancer Research (AIRC 5x1000, PRIN/2010NECHBX_004)
- Sapienza University of Rome (AIRC 5x1000, PRIN/2010NECHBX_004)
- Ministero dell'Istruzione, dell'Università e della Ricerca (AIRC 5x1000, PRIN/2010NECHBX_004)
This publication has 99 references indexed in Scilit:
- Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylationProceedings of the National Academy of Sciences, 2012
- Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomibBlood Cancer Journal, 2012
- Modulation of NKG2D-ligand Cell Surface Expression Enhances Immune Cell Therapy of CancerJournal of Immunotherapy, 2011
- Glycogen synthase kinase 3: A point of convergence for the host inflammatory responseCytokine, 2011
- Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaksNature, 2009
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- Differential Regulation of STAT Family Members by Glycogen Synthase Kinase-3Journal of Biological Chemistry, 2008
- MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myelomaProceedings of the National Academy of Sciences, 2008
- Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3Leukemia & Lymphoma, 2008
- Tumor stress, cell death and the ensuing immune responseCell Death & Differentiation, 2007